Electra Therapeutics Announces ELA026 Granted EMA Orphan Drug Designation for the Treatment of Secondary Hemophagocytic Lymphohistiocytosis (sHLH)
SOUTH SAN FRANCISCO, CA, August 4, 2025 – Electra Therapeutics, a clinical stage biotechnology company pioneering therapies against novel targets for diseases in immunology and cancer, today announced that the European Medicines Agency (EMA) has granted Orphan Drug…
